The current PEG ratio of 3.20 suggests that the market is pricing in aggressive long-term growth that may be difficult to sustain if the transition to lower-margin pharmacy channels continues to compress realized pricing. Investors should monitor whether this valuation multiple remains supported as the company shifts its focus toward the broader, yet lower-margin, non-intensive Type 2 diabetes population.

The low ROIC relative to the company's cost of capital suggests that the significant capital expenditures required for G7 production and facility automation are not yet yielding the expected efficiency gains. This trend warrants further investigation into whether the company can achieve higher returns as manufacturing yields stabilize and the product mix shifts toward higher-volume, lower-cost units.

The high inventory levels appear to reflect the strategic need to maintain buffer stocks during generational product transitions, such as the move from G6 to G7. Investors should monitor whether these working capital requirements normalize as the G7 becomes the primary revenue driver, as persistent inefficiencies could continue to weigh on free cash flow generation.

This reduction in leverage appears to provide the company with greater financial flexibility to navigate potential competitive shocks or regulatory changes in reimbursement. The improved interest coverage ratios suggest that the company is better positioned to manage its debt obligations, though investors should remain cautious of the high fixed-cost base that remains sensitive to volume fluctuations.